Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alcon Inc.
Proposal for simultaneous Rx and OTC sales of same drug at same dose and indication has CHPA hoping FDA acknowledges Pataday and Voltaren Arthritis Relief are competing with Rx equivalents even though elimination of prescription NDAs was part of approvals for the two switches.
During Q3, biopharma merger and acquisition value reached $15.4bn and drew in $37.6bn in potential deal value from alliances. Device company M&A values reached $550m, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $1.9bn.
Akorn agrees with DoJ to pay $7.9m to settle allegations it deliberately sold three as Rx three ingredients moved to OTC. Mislabeling led Medicare Part D to pay for the drugs for around a year despite the products not being eligible for coverage.
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
- OTC, Consumer
- Consumables, Central Supplies
- Implantable Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Alcon Laboratories, Inc.
- Alcon Universal SA
- Ivantis, Inc.
- Aerie Pharmaceuticals, Inc.